In patients with CLL receiving ibrutinib, expression of inhibitory receptors PD-1, and CD160, on T cells and immunosuppressive molecule CD200 on CLL decreased, and their expression levels were negatively correlated with the proliferative capacity of CAR-T cells during ex vivo expansion. Here, CD200 is linked to B-cell chronic lymphocytic leukemia.